Nova Eye Medical's proposed changes to local coverage determinations for minimally invasive glaucoma surgery by Medicare administrative contractors will not be implemented, maintaining reimbursement for canaloplasty procedures using the iTrack portfolio.
Effective Jan. 29, 2024, the decision averts restrictions on MIGS coverage, including canaloplasty, ensuring uninterrupted reimbursement.
Nova Eye Medical anticipates sustained sales growth in the USA, particularly for its iTrack Advance canaloplasty device launched in May.